NCT01499043View on ClinicalTrials.gov

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

PHASE2TerminatedINTERVENTIONAL

Enrollment

6

Participants

Timeline

Start Date

May 25, 2012

Primary Completion Date

March 11, 2013

Study Completion Date

March 11, 2013

Conditions

Prostate Cancer

Interventions

DRUG

PLX3397

Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Plexxikon

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY